• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Chemerin作为肥胖儿童肝内脂质含量的新型非侵入性血清标志物。

Chemerin as a novel non-invasive serum marker of intrahepatic lipid content in obese children.

作者信息

Kłusek-Oksiuta Monika, Bialokoz-Kalinowska Irena, Tarasów Eugeniusz, Wojtkowska Malgorzata, Werpachowska Irena, Lebensztejn Dariusz Marek

机构信息

Department of Pediatrics, Gastroenterology and Allergology, Medical University of Bialystok, 17 Waszyngtona St., Bialystok, 15-274, Poland.

Department of Pediatrics and Developmental Disorders, Medical University of Bialystok, Bialystok, Poland.

出版信息

Ital J Pediatr. 2014 Nov 17;40:84. doi: 10.1186/s13052-014-0084-4.

DOI:10.1186/s13052-014-0084-4
PMID:25399407
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4237733/
Abstract

BACKGROUND

Ectopic hepatic lipid accumulation is closely related to the development of insulin resistance, which is regarded as one of the most significant risk factors of non-alcoholic fatty liver disease (NAFLD). The current study has shown that fat tissue constitutes an important endocrine organ with its own production and metabolism of many biologically active substances, among which adipokines play an important role. Classic adipokines (e.g. leptin, adiponectin, resistin) are fat-derived hormones which serum level is altered in patients with NAFLD. The role of novel adipokines in the pathomechanism of this disease is not clear. Therefore, the aim of our study was to evaluate the serum concentrations of chemerin, omentin and vaspin in obese children with NAFLD.

METHODS

Forty-five obese children, aged 7-17 years old, were admitted to our Department with suspected liver disease (hepatomegaly, and/or ultrasonographic liver brightness, and/or increased ALT activity). Viral hepatitides, as well as autoimmune and metabolic liver diseases were excluded. Fasting serum levels of chemerin, omentin and vaspin were determined. The grade of liver steatosis in ultrasound was graded according to Saverymuttu. (1)HMR spectroscopy was performed with a 1.5 T scanner and with PRESS sequencing.

RESULTS

Fatty liver was confirmed in 39 children by ultrasound and in 33 patients by (1)HMRS (19 of them also had increased ALT activity /NAFLD/). Chemerin and vaspin levels were significantly higher in children with NAFLD compared to the control group (n = 30). The concentration of chemerin was significantly higher in children with advanced liver steatosis compared to non-hepatopathic patients (p = 0,02). Significant positive correlations were found between the total liver lipids in (1)HMRS and chemerin (r = 0,33; p = 0,02) and vaspin (r = 0,4; p = 0,006). The ability of serum chemerin (cut-off = 190 ng/ml, Se = 75%, Sp = 58%) to differentiate children with fatty liver in (1)HMRS from those without steatosis was significant (AUC = 0,7, p = 0,04). Omentin and vaspin did not allow a useful prediction to be made.

CONCLUSION

Chemerin seems to be the most suitable non-invasive biomarker in predicting both intrahepatic lipid content in obese children and advanced liver steatosis in children with NAFLD.

摘要

背景

肝脏异位脂质蓄积与胰岛素抵抗的发生密切相关,胰岛素抵抗被认为是非酒精性脂肪性肝病(NAFLD)最重要的危险因素之一。目前的研究表明,脂肪组织是一个重要的内分泌器官,自身能产生和代谢多种生物活性物质,其中脂肪因子起重要作用。经典脂肪因子(如瘦素、脂联素、抵抗素)是脂肪衍生的激素,NAFLD患者血清水平会发生改变。新型脂肪因子在该疾病发病机制中的作用尚不清楚。因此,我们研究的目的是评估NAFLD肥胖儿童血清中趋化素、网膜素和内脏脂肪素的浓度。

方法

45名7 - 17岁的肥胖儿童因疑似肝脏疾病(肝肿大和/或肝脏超声回声增强和/或ALT活性升高)入住我科。排除病毒性肝炎以及自身免疫性和代谢性肝病。测定空腹血清趋化素、网膜素和内脏脂肪素水平。肝脏脂肪变性程度根据萨韦勒穆图法进行超声分级。(1)使用1.5T扫描仪和PRESS序列进行磁共振波谱分析。

结果

39名儿童经超声确诊为脂肪肝,33名经(1)磁共振波谱分析确诊(其中19名ALT活性也升高/NAFLD/)。与对照组(n = 30)相比,NAFLD儿童的趋化素和内脏脂肪素水平显著更高。与无肝病患者相比,晚期肝脏脂肪变性儿童的趋化素浓度显著更高(p = 0.02)。在(1)磁共振波谱分析中,肝脏总脂质与趋化素(r = 0.33;p = 0.02)和内脏脂肪素(r = 0.4;p = 0.006)之间存在显著正相关。血清趋化素(临界值 = 190 ng/ml,敏感性 = 75%,特异性 = 58%)区分(1)磁共振波谱分析中有脂肪肝儿童和无脂肪变性儿童的能力显著(曲线下面积 = 0.7,p = 0.04)。网膜素和内脏脂肪素无法进行有效预测。

结论

趋化素似乎是预测肥胖儿童肝内脂质含量和NAFLD儿童晚期肝脏脂肪变性最合适的非侵入性生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ab1/4237733/7b82e02a6588/13052_2014_84_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ab1/4237733/7b82e02a6588/13052_2014_84_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ab1/4237733/7b82e02a6588/13052_2014_84_Fig1_HTML.jpg

相似文献

1
Chemerin as a novel non-invasive serum marker of intrahepatic lipid content in obese children.Chemerin作为肥胖儿童肝内脂质含量的新型非侵入性血清标志物。
Ital J Pediatr. 2014 Nov 17;40:84. doi: 10.1186/s13052-014-0084-4.
2
Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.非酒精性脂肪性肝病肥胖儿童血清神经酰胺浓度升高。
Lipids Health Dis. 2018 Sep 12;17(1):216. doi: 10.1186/s12944-018-0855-9.
3
Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease.非酒精性脂肪性肝病肥胖患儿血清脂联素、瘦素和抵抗素浓度。
Adv Med Sci. 2009;54(2):177-82. doi: 10.2478/v10039-009-0047-y.
4
Serum chemerin and vaspin in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中的血清chemerin和内脏脂肪素
Scand J Gastroenterol. 2010;45(2):235-42. doi: 10.3109/00365520903443852.
5
Serum Chemerin in Obese Children and Adolescents Before and After L-Carnitine Therapy: Relation to Nonalcoholic Fatty Liver Disease and Other Features of Metabolic Syndrome.左旋肉碱治疗前后肥胖儿童和青少年血清趋化素水平与非酒精性脂肪性肝病及代谢综合征其他特征的关系
Arch Med Res. 2016 Oct;47(7):541-549. doi: 10.1016/j.arcmed.2016.11.010.
6
Serum levels of chemerin, apelin, vaspin, and omentin-1 in obese type 2 diabetic Egyptian patients with coronary artery stenosis.患有冠状动脉狭窄的肥胖2型糖尿病埃及患者的血清chemerin、apelin、vaspin和网膜素-1水平。
Can J Physiol Pharmacol. 2018 Jan;96(1):38-44. doi: 10.1139/cjpp-2017-0272. Epub 2017 Sep 28.
7
Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity.肥胖患者内脏脂肪组织中chemerin表达降低与肝脂肪变性相关。
Obesity (Silver Spring). 2016 Dec;24(12):2544-2552. doi: 10.1002/oby.21674. Epub 2016 Oct 21.
8
Effects of rhythmic aerobic exercise plus core stability training on serum omentin, chemerin and vaspin levels and insulin resistance of overweight women.有节奏的有氧运动加核心稳定性训练对超重女性血清网膜素、chemerin和内脏脂肪素水平及胰岛素抵抗的影响
J Sports Med Phys Fitness. 2016 Apr;56(4):476-82. Epub 2015 Feb 5.
9
Chemerin as a marker of body fat and insulin resistance in women with polycystic ovary syndrome.在多囊卵巢综合征女性中,chemerin作为体脂和胰岛素抵抗的标志物。
Gynecol Endocrinol. 2015 Feb;31(2):152-5. doi: 10.3109/09513590.2014.968547. Epub 2014 Oct 8.
10
Chemerin, retinol binding protein-4, cytokeratin-18 and transgelin-2 presence in sera of patients with non-alcoholic liver fatty disease.非酒精性肝脂肪变性患者血清中凯莫瑞蛋白、视黄醇结合蛋白-4、细胞角蛋白-18和原肌球蛋白-2的存在情况
Ann Hepatol. 2016;15(6):862-869. doi: 10.5604/16652681.1222102.

引用本文的文献

1
Amino acid profile in overweight and obese prepubertal children - can simple biochemical tests help in the early prevention of associated comorbidities?超重和肥胖青春期前儿童的氨基酸谱——简单的生化测试能否有助于早期预防相关合并症?
Front Endocrinol (Lausanne). 2023 Oct 26;14:1274011. doi: 10.3389/fendo.2023.1274011. eCollection 2023.
2
Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease.儿童非酒精性脂肪性肝病中的无创生物标志物
World J Hepatol. 2023 May 27;15(5):609-640. doi: 10.4254/wjh.v15.i5.609.
3
Circulating chemerin level and the risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis.

本文引用的文献

1
Serum fetuin A concentration is elevated in children with non-alcoholic fatty liver disease.血清胎球蛋白 A 浓度在非酒精性脂肪性肝病患儿中升高。
Adv Med Sci. 2014 Mar;59(1):81-4. doi: 10.1016/j.advms.2013.08.003. Epub 2014 Mar 22.
2
Serum lipocalin-2, cathepsin S and chemerin levels and nonalcoholic fatty liver disease.血清脂联素-2、组织蛋白酶 S 和趋化素水平与非酒精性脂肪性肝病。
Mol Biol Rep. 2014 Mar;41(3):1317-23. doi: 10.1007/s11033-013-2977-5. Epub 2014 Jan 4.
3
Ectopic fat and cardiometabolic and vascular risk.异位脂肪与心脏代谢和血管风险。
循环趋化素水平与非酒精性脂肪性肝病风险:一项系统评价和荟萃分析。
J Diabetes Metab Disord. 2023 Jan 28;22(1):83-95. doi: 10.1007/s40200-023-01187-4. eCollection 2023 Jun.
4
Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?非酒精性脂肪性肝病中的脂肪因子:我们正朝着新的生物标志物和治疗靶点迈进吗?
Biology (Basel). 2022 Aug 19;11(8):1237. doi: 10.3390/biology11081237.
5
Chemerin as Potential Biomarker in Pediatric Diseases: A PRISMA-Compliant Study.凯莫瑞蛋白作为儿科疾病潜在生物标志物的一项遵循PRISMA规范的研究。
Biomedicines. 2022 Mar 3;10(3):591. doi: 10.3390/biomedicines10030591.
6
The "Adipo-Cerebral" Dialogue in Childhood Obesity: Focus on Growth and Puberty. Physiopathological and Nutritional Aspects.儿童肥胖中的“脂肪-大脑”对话:关注生长和青春期。病理生理和营养方面。
Nutrients. 2021 Sep 28;13(10):3434. doi: 10.3390/nu13103434.
7
Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy.减重对小儿非酒精性脂肪性肝病的疗效:通过药物治疗改善治疗结局的机会。
Front Endocrinol (Lausanne). 2021 Apr 13;12:663351. doi: 10.3389/fendo.2021.663351. eCollection 2021.
8
From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction?从非酒精性脂肪性肝病(NAFLD)到代谢功能障碍相关脂肪性肝病(MAFLD)——儿科患者的新术语,是朝着良好科学方向迈出的一步吗?
J Clin Med. 2021 Mar 1;10(5):924. doi: 10.3390/jcm10050924.
9
Pediatric non-alcoholic fatty liver disease: current perspectives on diagnosis and management.小儿非酒精性脂肪性肝病:诊断与管理的当前观点
Pediatric Health Med Ther. 2019 Aug 23;10:89-97. doi: 10.2147/PHMT.S188989. eCollection 2019.
10
Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children.儿童非酒精性脂肪性肝病的发病机制、诊断与治疗进展
Clin Exp Hepatol. 2019 Mar;5(1):11-21. doi: 10.5114/ceh.2019.83152. Epub 2019 Feb 20.
Int J Cardiol. 2013 Nov 5;169(3):166-76. doi: 10.1016/j.ijcard.2013.08.077. Epub 2013 Sep 7.
4
Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease.人非酒精性脂肪性肝病中肝组织 chemerin mRNA 表达升高。
Eur J Endocrinol. 2013 Oct 1;169(5):547-57. doi: 10.1530/EJE-13-0112. Print 2013 Nov.
5
Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver.Chemerin 在肝细胞中高度表达,并在非酒精性脂肪性肝炎肝中被诱导。
Exp Mol Pathol. 2013 Oct;95(2):199-205. doi: 10.1016/j.yexmp.2013.07.009. Epub 2013 Jul 29.
6
Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets.小儿非酒精性脂肪性肝病:发育、进展、代谢见解和潜在治疗靶点的新概念。
BMC Pediatr. 2013 Mar 25;13:40. doi: 10.1186/1471-2431-13-40.
7
Identification of chemerin as a novel FXR target gene down-regulated in the progression of nonalcoholic steatohepatitis.鉴定 chemerin 为非酒精性脂肪性肝炎进展过程中受下调的新型 FXR 靶基因。
Endocrinology. 2013 May;154(5):1794-801. doi: 10.1210/en.2012-2126. Epub 2013 Mar 18.
8
Serum fetuin A and chemerin levels correlate with hepatic steatosis and regional adiposity in maintenance hemodialysis patients.维持性血液透析患者血清胎球蛋白 A 和趋化素水平与肝脂肪变性和局部肥胖相关。
PLoS One. 2012;7(7):e38415. doi: 10.1371/journal.pone.0038415. Epub 2012 Jul 16.
9
Systemic inflammation in childhood obesity: circulating inflammatory mediators and activated CD14++ monocytes.儿童肥胖症中的系统性炎症:循环炎症介质和激活的 CD14++单核细胞。
Diabetologia. 2012 Oct;55(10):2800-2810. doi: 10.1007/s00125-012-2641-y. Epub 2012 Jul 18.
10
Chemerin as a mediator between obesity and vascular inflammation in children.Chemerin 作为肥胖与儿童血管炎症之间的中介物。
J Clin Endocrinol Metab. 2012 Apr;97(4):E556-64. doi: 10.1210/jc.2011-2937. Epub 2012 Mar 21.